New diabetes clinical trial: A Study to Evaluate Time in Range in Type 2 Diabetics Using Afrezza® Plus Basal Insulin Compared to Multiple Daily Injections

Published on: October 14, 2019 at 09:30PM
Condition:   Type 2 Diabetes Treated With Insulin
Intervention:   Drug: Afrezza Inhalant Product
Sponsors:   Diabetes and Glandular Disease Clinic;   Mannkind Corporation;   DexCom, Inc.
Recruiting
https://ift.tt/2IOFIa0